Bone Health

Hematology

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Respiratory

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).


FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz

At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

At the American Academy of Dermatology annual meeting, Samsung Bioepis shared positive results from a phase 1 study comparing its ustekinumab biosimilars (SB17) with the reference product (Stealara).

Samsung Bioepis’ Stelara Biosimilar Proves Successful in Phase 1 Study

On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.

How Community Oncologists Can Break Down Biosimilar Adoption Barriers

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

conference

1rem

AAAAI Annual Meeting

A phase 1 study testing Celltrion Healthcare’s omalizumab biosimilar in healthy subjects showed similar safety and pharmacokinetic profiles to the reference product (Xolair), as presented at the American Academy of Allergy Asthma and Immunology’s annual meeting.

Celltrion Biosimilar Demonstrates Equivalence With Xolair in Phase 1 Study

Omalizumab Biologic is Changing the Face of Asthma Therapeutics

Dupilumab Improves Signs and Symptoms of Atopic Dermatitis Without Safety Issues

Fewer AEs With Humanized Antibody Treatments Favorable for Biosimilar Development 

Case Study Indicates IVIG May Counteract Adalimumab

Dexpramipexole Lowers Blood and Tissue Eosinophils Without Severe Adverse Reactions